{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:09:53Z","timestamp":1771409393747,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":134,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20271"],"award-info":[{"award-number":["U22A20271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2022-2-2067"],"award-info":[{"award-number":["2022-2-2067"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["D171100006817001"],"award-info":[{"award-number":["D171100006817001"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20271"],"award-info":[{"award-number":["U22A20271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["D171100006817001"],"award-info":[{"award-number":["D171100006817001"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) is often underdiagnosed. This study evaluates the HFpEF-ABA score's ability to identify high-risk, undiagnosed HFpEF subgroups with elevated cardiovascular event rates and assesses the impact of intensive blood pressure control in these populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post-hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) was performed. The HFpEF-ABA score identified high-risk individuals with undiagnosed HFpEF. Cox proportional hazards regression was used to examine interactions between HFpEF-ABA score groups and intensive blood pressure control on major cardiovascular outcomes. The primary outcome was a composite of myocardial infarction (MI), acute coronary syndrome not resulting in MI, stroke, acute decompensated heart failure and cardiovascular disease death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 9265 patients (mean age, 67.9 \u00b1 9.4 years; 35.5% females), 559 primary outcomes occurred during a median follow-up of 3.2 years. An HFpEF-ABA score \u2265 90% was associated with a higher risk of the primary outcome [adjusted hazard ratio (aHR), 1.96 (1.57\u20132.44); P &amp;lt; 0.001]. When treated as a continuous variable, higher HFpEF-ABA scores were independently associated with an increased risk of the primary composite outcome (P = 0.001), with a modest non-linear relationship observed (P for non-linearity = 0.040). In the intensive treatment group, the absolute reduction in primary outcomes was 5.0 per 1000 patient-years for scores &amp;lt; 90% and 11.2 per 1000 patient-years for \u2265 90%. Intensive blood pressure control reduced primary outcomes in both groups [&amp;lt;90%: aHR, 0.75 (0.62\u20130.90); \u226590%: aHR, 0.76 (0.51\u20131.13)] with no significant heterogeneity (P for interaction = 0.944). Serious adverse events did not increase in either group [&amp;lt;90%: aHR, 1.04 (0.96\u20131.11); \u226590%: aHR, 1.06 (0.88\u20131.28); P for interaction = 0.801].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HFpEF-ABA score identifies high-risk patients with undiagnosed HFpEF who have elevated cardiovascular event rates and benefit from intensive blood pressure control without an increased risk of serious adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15435","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:17:59Z","timestamp":1759882679000},"page":"4277-4287","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Cardiovascular Benefits of Intensive Blood Pressure Lowering in High-Risk Undiagnosed HFpEF Patients"],"prefix":"10.1093","volume":"12","author":[{"given":"Xinru","family":"Liu","sequence":"first","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Hua","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Wu","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Tang","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Xiong","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Lv","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzeng","family":"Dong","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]},{"name":"Department of Cardiology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Center of Heart Failure and Cardiomyopathy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]},{"name":"Heart Health Research Center (HHRC) , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2026021804170857700_ehf215435-bib-0001","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804170857700_ehf215435-bib-0002","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026021804170857700_ehf215435-bib-0003","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ejhf.2747","article-title":"Central hemodynamic abnormalities and outcome in patients with unexplained dyspnea","volume":"25","author":"Omote","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"2026021804170857700_ehf215435-bib-0004","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circulation: Heart Failure"},{"key":"2026021804170857700_ehf215435-bib-0005","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026021804170857700_ehf215435-bib-0006","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026021804170857700_ehf215435-bib-0007","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","article-title":"Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community","volume":"8","author":"Selvaraj","year":"2020","journal-title":"JACC: Heart Failure"},{"key":"2026021804170857700_ehf215435-bib-0008","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation."},{"key":"2026021804170857700_ehf215435-bib-0009","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score","volume":"30","author":"Reddy","year":"2024","journal-title":"Nat Med"},{"key":"2026021804170857700_ehf215435-bib-0010","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-023-02567-2","article-title":"Recent successes in heart failure treatment","volume":"29","author":"Lam","year":"2023","journal-title":"Nat Med"},{"key":"2026021804170857700_ehf215435-bib-0011","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804170857700_ehf215435-bib-0012","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021804170857700_ehf215435-bib-0013","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804170857700_ehf215435-bib-0014","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021804170857700_ehf215435-bib-0015","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clin Trials."},{"key":"2026021804170857700_ehf215435-bib-0016","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ejhf.3115","article-title":"Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction","volume":"26","author":"Wu","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804170857700_ehf215435-bib-0017","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/CLEP.S253612","article-title":"Risk factors for heart failure with preserved or reduced ejection fraction among Medicare beneficiaries: application of competing risks analysis and gradient boosted model","volume":"12","author":"Lee","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2026021804170857700_ehf215435-bib-0018","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10741-018-9698-8","article-title":"The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?","volume":"23","author":"Tadic","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026021804170857700_ehf215435-bib-0019","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021804170857700_ehf215435-bib-0020","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"2026021804170857700_ehf215435-bib-0021","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021804170857700_ehf215435-bib-0022","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/ejhf.1976","article-title":"Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF","volume":"22","author":"Vaduganathan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804170857700_ehf215435-bib-0023","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804170857700_ehf215435-bib-0024","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41440-019-0216-8","article-title":"Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"42","author":"Kawano","year":"2019","journal-title":"Hypertens Res"},{"key":"2026021804170857700_ehf215435-bib-0025","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021804170857700_ehf215435-bib-0026","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008322","article-title":"Incidence and outcomes of acute heart failure with preserved versus reduced ejection fraction in SPRINT","volume":"14","author":"Upadhya","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021804170857700_ehf215435-bib-0027","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary","volume":"141","author":"Sj","year":"2020","journal-title":"Circulation"},{"key":"2026021804170857700_ehf215435-bib-0028","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021804170857700_ehf215435-bib-0029","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11906-020-1017-9","article-title":"Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy","volume":"22","author":"Nwabuo","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2026021804170857700_ehf215435-bib-0030","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail."},{"key":"2026021804170857700_ehf215435-bib-0031","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1152\/japplphysiol.00374.2015","article-title":"Myocardial hypertrophy and its role in heart failure with preserved ejection fraction","volume":"119","author":"Heinzel","year":"2015","journal-title":"J Appl Physiol (1985)"},{"key":"2026021804170857700_ehf215435-bib-0032","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/HYPERTENSIONAHA.109.138529","article-title":"Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction","volume":"55","author":"Solomon","year":"2010","journal-title":"Hypertension"},{"key":"2026021804170857700_ehf215435-bib-0033","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/eurheartj\/ehs299","article-title":"Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency","volume":"34","author":"Lam","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021804170857700_ehf215435-bib-0034","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0002-9343(03)00158-x","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"2026021804170857700_ehf215435-bib-0035","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"2026021804170857700_ehf215435-bib-0036","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2337\/dc08-0371","article-title":"Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)","volume":"31","author":"Ruggenenti","year":"2008","journal-title":"Diabetes Care."},{"key":"2026021804170857700_ehf215435-bib-0037","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ajh.2008.16","article-title":"Left ventricular hypertrophy and clinical outcomes in hypertensive patients","volume":"21","author":"Ruilope","year":"2008","journal-title":"Am J Hypertens"},{"key":"2026021804170857700_ehf215435-bib-0038","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/HYPERTENSIONAHA.119.13073","article-title":"Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the SPRINT-HEART","volume":"74","author":"Upadhya","year":"2019","journal-title":"Hypertension"},{"key":"2026021804170857700_ehf215435-bib-0039","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/S0140-6736(07)60980-5","article-title":"Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial","volume":"369","author":"Solomon","year":"2007","journal-title":"Lancet"},{"key":"2026021804170857700_ehf215435-bib-0040","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13247","article-title":"Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction","volume":"8","author":"Gozdzik","year":"2021","journal-title":"ESC heart failure."}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4277\/66967828\/eschf_12_6_4277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4277\/66967828\/eschf_12_6_4277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:17:12Z","timestamp":1771406232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4277\/8488176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15435","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"2025-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}